Factors associated with meropenem pharmacokinetic/pharmacodynamic target attainment in septic critically ill patients treated with extended intermittent infusion or continuous infusion

This publication has 14 references indexed in Scilit:

• Global increase and geographic convergence in antibiotic consumption between 2000 and 2015
  Proceedings of the National Academy of Sciences, 2018
• Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae
  Antimicrobial Agents and Chemotherapy, 2017
• Too much of a good thing: a retrospective study of β-lactam concentration–toxicity relationships
  Journal of Antimicrobial Chemotherapy, 2017
• Simultaneous Determination of Eight β-Lactam Antibiotics, Amoxicillin, Cefazolin, Cefepime, Cefotaxime, Ceftazidime, Cloxacillin, Oxacillin, and Piperacillin, in Human Plasma by Using Ultra-High-Performance Liquid Chromatography with Ultraviolet Detection
  Antimicrobial Agents and Chemotherapy, 2016
• Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients
  Antimicrobial Agents and Chemotherapy, 2016
• Continuous beta-lactam infusion in critically ill patients: the clinical evidence
  Annals of Intensive Care, 2012
• The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients
  Clinical Pharmacokinetics, 2011
• Stability of meropenem and doripenem solutions for administration by continuous infusion
  Journal of Antimicrobial Chemotherapy, 2010
• Comparative Review of the Carbapenems
  Drugs, 2007
• Pharmacokinetics of Meropenem in Patients with Renal Failure and Patients Receiving Renal Replacement Therapy
  Clinical Pharmacokinetics, 2000